Key result
Aldosterone antagonists reduced the risk of sudden cardiac death by 21% in patients with heart failure (RR 0.79; 95% CI 0.67-0.93).
Why the study?
Do aldosterone antagonists reduce the risk of sudden cardiac death and ventricular arrhythmias in patients with heart failure or coronary artery disease?
Meta-Analysis (n=8,635)
Do aldosterone antagonists reduce the risk of sudden cardiac death and ventricular arrhythmias in patients with heart failure or coronary artery disease?
Relative Risk: 0.79 (95% CI 0.67–0.93)
Aldosterone antagonists significantly reduce the risk of sudden cardiac death and ventricular arrhythmias in patients with heart failure or coronary artery disease.
No takes yet. Share an insight, caveat, or question.
Supports aldosterone antagonist use to reduce sudden cardiac death in heart failure; confirms benefit across randomized trials in meta-analysis.
Wei et al. (2010) conducted a meta-analysis in Heart failure or coronary artery disease (n=8,635). Aldosterone antagonists was evaluated on Sudden cardiac death (RR 0.79, 95% CI 0.67-0.93). Aldosterone antagonists reduced the risk of sudden cardiac death by 21% in patients with heart failure (RR 0.79; 95% CI 0.67-0.93).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: